~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK™ to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~ ~ Company Has Approximately $27 Million in Cash and No Outstanding Debt ~ RESEARCH TRIANGLE PARK, N.C.

~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™ ~ ~ Resubmission of the NDA for PEDMARK TM is Planned for the Second Quarter of 2021 ~ ~ Company Has Approximately $30 Million in Cash and No Outstanding

~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™  ~ ~ No Clinical Safety or Efficacy Issues Identified ; No Additional Studies Required   for PEDMARK™  ~ ~   The Company Has Approximately $33

RESEARCH TRIANGLE PARK, N.C. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity

RESEARCH TRIANGLE PARK, N.C. , Aug. 12, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. , a specialty pharmaceutical company, today announced that Rosty Raykov , Chief Executive Officer of Fennec will present at the following upcoming investor conferences.

~ No Clinical Safety or Efficacy Issues Identified, and No Requirement for Further Clinical Data ~ ~ FDA Pre-Approval Inspection has Identified Deficiencies with the Facility of the Drug Product Manufacturer, which Require Resolution Prior to PEDMARK Approval ~ ~ Company to Host Conference Call and

~ FDA Set a PDUFA Target Action Date for PEDMARK TM of August 10, 2020 ~ ~ Strong Financial Position with $38.7 million in cash and no debt ~ RESEARCH TRIANGLE PARK, N.C. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company

RESEARCH TRIANGLE PARK, N.C. , June 26, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in

RESEARCH TRIANGLE PARK, N.C. , June 22, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 7, 2020 (the “Circular”) for the Annual General and Special Meeting of